Role of Glycated Albumin during Pregnancy

Albumin Glikat pada Kehamilan

Suzanna Immanuel¹, Thoeng Ronald¹, Kanadi Sumapradja², Arini Setiawati³

¹Department of Clinical Pathology
²Department of Obstetrics and Gynecology
³Department of Pharmacology and Therapeutics
Faculty of Medicine Universitas Indonesia/
Dr. Cipto Mangunkusumo Hospital
Jakarta

INTRODUCTION

In 2013, International Diabetes Federation (IDF) estimated that 21.4 million women in the world suffering from hyperglycemia in pregnancy. It was estimated that 16% of them suffered from gestational diabetes mellitus (GDM); thus, it required close monitoring during pregnancy and after childbirth. Southeast Asia had the highest prevalence of hyperglycemia in pregnancy at 25.0% compared with Europe at 12.6% (table 1).¹

Untreated hyperglycemia can lead to several complications both to the mother and fetal, such as impaired invasion of cytotrophoblast that causes placental hypoxia releasing antiangiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) resulting to preeclampsia, premature birth, fetal hyperinsulinemia that causes diabetic fetopathy including macrosomia, increasing the cesarean section rate, perinatal trauma, neonatal hypoglycemia, and fetal death. International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommends screening for diagnosis of GDM using oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The procedure is through dissolving 75 grams of glucose to 200 ml water for all pregnant women.¹⁻⁵

We need an indicator not only as a tool for monitoring the glycemic status during pregnancy, but also to predict about possible complication for mother and baby.

Abstract

Objective: To determine the glycated albumin profile during pregnancy with normal glycemic status.

Methods: We recruited 60 pregnant women between 21 and 36 weeks of gestation. We conducted several laboratory tests, such as glycated albumin, blood glucose, and albumin. These parameters were compared among four groups of gestational age (21-24 weeks, 25-28 weeks, 29-32 weeks, and 33-36 weeks) using ANOVA or Kruskal-Wallis test continued by Post-hoc test.

Results: Glycated albumin was not statistically different among the groups. Albumin level of 33-36 weeks of gestation women (3.6 (SD 0.2) g/dl) was lower than 21-24 weeks of gestation women (3.8 (SD 0.2) g/dl).

Conclusion: Glycated albumin level is not affected by gestational age. Therefore, glycated albumin may be used as glycemic status indicator during pregnancy from 21 to 36 weeks.

Keywords: HbA1c, glycated albumin, glycemic status, pregnancy

Abstrak

Tujuan: Mengetahui karakteristik albumin glikat pada kehamilan dengan status glikemik normal.


Hasil: Kadar albumin glikat tidak berbeda antara kelompok usia kehamilan. Kadar albumin pada kelompok kehamilan 33-36 minggu (3.6 (SB 0.2) g/dl) lebih rendah dibandingkan kelompok kehamilan 21-24 minggu (3.8 (SB 0.2) g/dl).

Kesimpulan: Kadar albumin glikat tidak terpengaruh dengan usia kehamilan. Albumin glikat dapat menjadi penanda status glikemik pada usia kehamilan 21-36 minggu.

Kata kunci: albumin glikat, HbA1c, kehamilan, status glikemik

Correspondence: Thoeng Ronald; thoeng.ronald@hotmail.com
Glycated albumin is a new indicator for monitoring glycemic status which is not affected by the condition of anemia. Glycated albumin is formed through a process of non-enzymatic glycation, in which glucose is covalently bonded to the amino acid residues such as lysine, arginine, cysteine of albumin. Through Amadori reaction, it forms ketoamine stable form. Glycated albumin can indicate glycemic status for the previous 2 weeks because albumin half-life is only 15-20 days. Therefore, glycated albumin can be used to monitor short-term glycemic status. Study by Hashimoto, et al. on 47 pregnant women with gestational age of 21-36 weeks found glycated albumin level was not influenced by gestational age. This study aims to determine the profile glycated albumin during pregnancy with normal glycemic status.

METHODS

This was a cross-sectional study design which recruited 60 pregnant women with 21 to 36 weeks of gestation. The study was conducted from April to May 2016 and it was approved by the ethics committee of the Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia with the approval number of 260/UN2.F1/ETHICS/2016.

We divided sixty pregnant women at gestational age 21-36 weeks into four groups: 17 subjects in group I (21-24 weeks of gestation), 11 subjects in group II (25-28 weeks of gestation), 16 subjects in group III (29-32 weeks of gestation), and 16 subjects in group IV (33-36 weeks of gestation). The inclusion criteria were all pregnant women with blood glucose levels less than 200 mg/dl and we excluded women with thyroid disease, cirrhosis, diabetes, proteinuria, and corticosteroid therapy. We took 4 ml serum for assessing glycated albumin, albumin, and blood glucose.

Glycated albumin level was measured using the reagent Lucica®GA-L (Asahi Kasei Pharma). Blood glucose was measured using a Cobas C 501 (Roche Holding AG).

Differences among groups were obtained through normality test of each group. The normally distributed data were shown in mean and standard of deviation; unless the data were described in median and minimum to maximum. After that, we held the one-way ANOVA and continued by analysis of Bonferroni or Tukey multiple comparison. If distribution of data was not normal and/or its variance was not homogeneous, we did the Kruskal-Wallis test followed by Mann Whitney U post-hoc analysis between group. We performed the statistical test using SPSS version 20.

RESULTS

Glycated albumin level did not differ significantly among four groups (p=0.061). Level of albumin in group of women with gestational age 33-36 weeks (3.6 (SD 0.2) g/dl) was significantly lower than 21-24 weeks of gestation group (3.8 (SD 0.2) g/dl) (p=0.006). Table 2 depicted the characteristics of study subjects in each gestational age.


DISCUSSION

In this study, there was no significant difference in glycated albumin level between gestation groups. These results were similar to study by Hashimoto, et al. It was due to similar subjects of Asian population. This study found level of albumin in group IV (33-36 weeks of gestation) significantly was lower than the level of albumin in group I (21-24 weeks of gestation); this might be due to hemodilution. The hemodilution normally occurs because of the plasma volume increase in pregnancy. Glycated albumin level was not influenced by hemodilution because the result in the form of glycated albumin level is a ratio of glycated albumin to albumin.

CONCLUSION

Glycated albumin level is not affected by gestational age. Therefore, glycated albumin may be used as glycemic status indicator during pregnancy from 21 to 36 weeks.

REFERENCES